M&A Deal Summary

Aegerion Pharmaceuticals Acquires Myalept

On November 6, 2014, Aegerion Pharmaceuticals acquired medical products company Myalept from AstraZeneca for 325M USD

Acquisition Highlights
  • This is Aegerion Pharmaceuticals’ 1st transaction in the Medical Products sector.
  • This is Aegerion Pharmaceuticals’ largest (disclosed) transaction.
  • This is Aegerion Pharmaceuticals’ 1st transaction in the United States.

M&A Deal Summary
Date 2014-11-06
Target Myalept
Sector Medical Products
Buyer(s) Aegerion Pharmaceuticals
Sellers(s) AstraZeneca
Deal Type Divestiture
Deal Value 325M USD

Target

Myalept

United States
Myalept™ (metreleptin for injection) is an orphan product that is indicated to treat complications of leptin deficiency in patients with generalized lipodystrophy.

Search 198,242 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Aegerion Pharmaceuticals

Cambridge, Massachusetts, United States
Category Company
Founded 2005
Sector Life Science
Employees307
Revenue 240M USD (2015)
DESCRIPTION

Aegerion Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of pharmaceutical products to treat cardiovascular and metabolic diseases. Aegerion Pharmaceuticals, Inc. was formed in 2005 and is headquartered in Cambridge, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector (Medical Products) 1 of 1
Type (Divestiture) 1 of 1
Country (United States) 1 of 1
Year (2014) 1 of 1
Size (of disclosed) 1 of 1

Seller(S) 1

SELLER

AstraZeneca

Cambridge, United Kingdom
Category Company
Founded 1992
Sector Life Science
Employees83,100
Revenue 45.8B USD (2023)
DESCRIPTION
Main office on AstraZeneca's campus in Waltham, Massachusetts.
Main office on AstraZeneca's campus in Waltham, Massachusetts.

AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. The Company's aim is to improve the health and quality of life of patients around the world through medicines, treatment solutions, and accessibility to healthcare. AstraZeneca is involved in both the research and development (R&D) and manufacturing of drugs to address critical areas of unmet medical need. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.

DEAL STATS #
Overall 5 of 11
Sector (Medical Products) 2 of 3
Type (Divestiture) 5 of 11
Country (United States) 3 of 3
Year (2014) 2 of 2
Size (of disclosed) 3 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-11-04 Definiens AG

Munich, Germany

Definiens AG is a provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived from other sources.

Buy $150M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-07-27 Caprelsa

United Kingdom

Caprelsa SA is a rare disease therapy medicine, indicated for the treatment of symptomatic or progressive medullary thyroid carcinoma in patients with unresectable locally advanced or metastatic disease.

Sell -
Mergr

Product

Company

Legal